The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization

The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of several disease maps and experimental data focused on SARS-CoV-2 / COVID-19 pathophysiology. By applying a systematic approach, we were able to predict the effect of drug pairs on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates.

[1]  Wei Cao,et al.  COVID-19: towards understanding of pathogenesis , 2020, Cell Research.

[2]  Martin Hofmann-Apitius,et al.  ComPath: an ecosystem for exploring, analyzing, and curating mappings across pathway databases , 2018, npj Systems Biology and Applications.

[3]  S. Jois,et al.  The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, bioRxiv.

[4]  Dominic Winter,et al.  Comprehensive draft of the mouse embryonic fibroblast lysosomal proteome by mass spectrometry based proteomics , 2020, Scientific Data.

[5]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[6]  Roland Eils,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[7]  Martin Hofmann-Apitius,et al.  Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis , 2015, Alzheimer's & Dementia.

[8]  Y. Benjamini.  Discovering the false discovery rate , 2010 .

[9]  Jindrich Cinatl,et al.  HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.

[10]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[11]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[12]  Farhana Musarrat,et al.  The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, Journal of medical virology.

[13]  C. Buckee,et al.  Wrong but Useful - What Covid-19 Epidemiologic Models Can and Cannot Tell Us. , 2020, The New England journal of medicine.

[14]  Torsten Schwede,et al.  A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0 , 2020, International journal of molecular sciences.

[15]  Jonas Ardö,et al.  The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data , 2020, Scientific Data.

[16]  A. Barabasi,et al.  Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2020, Proceedings of the National Academy of Sciences.

[17]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[18]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[19]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[20]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[21]  Denisa Bojkova,et al.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China , 2020, The New England journal of medicine.

[22]  M. Lipsitch,et al.  Defining the Epidemiology of Covid-19 - Studies Needed. , 2020, The New England journal of medicine.

[23]  John S. Brownstein,et al.  Epidemiological data from the COVID-19 outbreak, real-time case information , 2020, Scientific Data.

[24]  Martin Hofmann-Apitius,et al.  PathMe: merging and exploring mechanistic pathway knowledge , 2018, BMC Bioinformatics.

[25]  Lin Cheng,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[26]  S. Ciesek,et al.  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection , 2020 .

[27]  E. Barillot,et al.  Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps , 2015, Oncogenesis.

[28]  Andrew I. Su,et al.  The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis , 2018, Proceedings of the National Academy of Sciences.

[29]  Hiroaki Kitano,et al.  COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms , 2020, Scientific Data.

[30]  T. Pawson,et al.  Network medicine , 2008, FEBS letters.

[31]  Samik Ghosh,et al.  Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map , 2013, Molecular Neurobiology.

[32]  Samik Ghosh,et al.  A comprehensive map of the influenza A virus replication cycle , 2013, BMC Systems Biology.

[33]  Ted Slater,et al.  Recent advances in modeling languages for pathway maps and computable biological networks. , 2014, Drug discovery today.

[34]  Sam Michael,et al.  Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro , 2020, bioRxiv.

[35]  Martin Hofmann-Apitius,et al.  COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology , 2020, bioRxiv.

[36]  Martin Hofmann-Apitius,et al.  COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology , 2020, bioRxiv.

[37]  Joel R. Huff,et al.  HIV Protease Inhibitor , 1992 .

[38]  Ruth R. Montgomery,et al.  Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium , 2020, bioRxiv.

[39]  Ruth R. Montgomery,et al.  Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells , 2020 .